Pierre Fabre hires XtalPi's AI and robotics platform to design cancer drug candidates

Laboratoires Pierre Fabre has signed a drug discovery agreement with XtalPi, the Shenzhen-based AI and robotics company listed in Hong Kong, under which XtalPi will design new small molecule candidates for several Pierre Fabre research programmes. The two companies announced the deal on 9 November 2026¹.

What the agreement covers

XtalPi will apply its AI capabilities and its robotics platform to design small molecules de novo against targets the partners have not named¹. The programmes sit mainly in oncology, with dermatology and rare diseases mentioned as possible further areas¹.

The division of labour is clear in the announcement. Pierre Fabre brings disease biology, discovery, translational research and clinical development expertise, picks the most promising compounds and takes sole responsibility for clinical and commercial development once candidates emerge¹. XtalPi's role ends at the delivery of candidates.

The partners say they will focus on targets that have historically been hard to drug¹. The terms include an upfront payment, several milestone payments and downstream economic participation, but neither company has disclosed the amounts¹.

Francesco Hofmann, who heads pharma research and development at Pierre Fabre, called the partnership "a critical addition to our R&D Data and AI roadmap and to our discovery engine"¹. Raymond Zheng, head of integrated drug discovery at XtalPi, said the aim is to "advance promising preclinical candidates to benefit patients with unmet medical needs"¹.

What it means for the market

Pierre Fabre is buying AI-led design capacity from an outside specialist rather than relying only on its own chemistry teams. The company frames the agreement as a way to strengthen its own discovery capabilities, which suggests outsourced design work is being treated as part of the company's core R&D plan rather than a side experiment¹.

For XtalPi, the agreement extends its business of selling de novo design and automated chemistry to established drugmakers. The structure, with an upfront fee, milestones and downstream participation, ties part of XtalPi's return to whether the molecules it designs progress through Pierre Fabre's pipeline¹.

For competing AI discovery vendors, the deal shows a Chinese platform winning work from a European oncology company. How large that work is remains unknown, because neither the number of programmes nor the value of the payments has been published¹.

Caveats

The announcement is the companies' own statement and no independent figures are available. The targets are undisclosed and all of the work is at the discovery stage, so the agreement says nothing yet about whether XtalPi's designs will reach the clinic¹. The companies give no timeline for the first candidates, and the stated goal is limited to delivering preclinical candidates that Pierre Fabre would then choose whether to develop¹.